Insilico's AI drug platform wins big pharma deals and turns profitable
Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.
These are the largest new partnerships this period and directly boost demand for Insilico's platform.
First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.
Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.
Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.
Index inclusion is a new capital-flow catalyst that can support the share price.
Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.
It explains the broader industry force behind Insilico's deal momentum and investor interest.